Company intelligence / Profile preview

Scilex Pharmaceuticals

Palo Alto, California, USAscilexholding.com ↗
Ownership
Public · SCLX
Development stage
Commercial
01

Overview

Scilex has three FDA-approved non-opioid products on the market and several late-stage pipeline candidates. ZTlido® shows strong sales growth and international distribution deals. SP‑102 met primary and secondary endpoints in pivotal phase 3 trial. SP‑103 completed phase II with clear path to NDA after phase III; projected blockbuster potential. SP‑104 completed multiple phase I trials.

Therapeutic areas
NeurologyRheumatology
Modalities
Small moleculeBiologicDevice (topical patch)Viscous gel formulation
Industry
Biotech
02

Drug pipeline

2 assets

ZTlido

Commercial
Indications
Post-herpetic neuralgia

1 more asset in the full pipeline.

Request access →
03

Partnerships

Joint venture “Scilex Bio” formed with IPMC/Bio Innovation Consortium to develop KDS2010 (MAO-B inhibitor) for obesity/neurodegenerative diseases including Alzheimer’s disease
04

Financials

Market cap
$45.6M
Total revenue
$7.6M
Enterprise value
$140.6M

Beyond the preview

Go deeper on Scilex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scilex Pharmaceuticals.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call